EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study

Darren Jun Hao Tan, Nobuharu Tamaki iD, Beom Kyung Kim iD, Karn Wijarnpreecha iD, Majd Bassam Aboona, Claire Faulkner, Charlotte Kench, Shirin Salimi, Abdul-Hamid Sabih, Wen Hui Lim, Pojsakorn Danpanichkul iD, Benjamin Tay und 11 weitere

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18346 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Darren Jun Hao Tan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NUHS Clinician Scientist Programme, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Major society guidelines recommend the fibrosis‐4 index (FIB‐4) as the initial step to risk stratifying people with metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to evaluate the proportion of people with MASLD‐related hepatocellular carcinoma (HCC) and a low FIB‐4.

Methods

This cohort study included 613 consecutive adults (33% female) diagnosed with MASLD‐related HCC from January 2008 to August 2023 at seven international centres in Australia, India, Japan, South Korea, Singapore and the United States. The primary objective was to determine the proportion of participants with a low FIB‐4, defined as FIB‐4 < 1.3, or < 2 if age > 65 years, in people without cirrhosis.

Results

The mean (±SD) age and body mass index were 71 (±11) years and 27 (±7) kg/m 2 , respectively. Overall, 235 participants (38%) did not have known cirrhosis. The median FIB‐4 was 3.90 (IQR 2.42–6.42). A total of 78 participants (13%) had a low FIB‐4. Among participants without known cirrhosis ( n = 235), 62 participants (26%) had a low FIB‐4. Participants with a low FIB‐4 had larger median total tumour diameter ( p < 0.001) and lower median serum alpha‐fetoprotein ( p = 0.005), compared to participants without a low FIB‐4. Cirrhosis was associated with lower odds of low FIB‐4, but not other factors such as male sex, type 2 diabetes, or obesity.

Conclusion

More than a quarter of those with MASLD‐related HCC without cirrhosis have a low FIB‐4. The proposed clinical care pathways may not identify these people for further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMaleFemaleAgedMiddle AgedPrevalenceLiver CirrhosisFatty LiverAged, 80 and overCohort StudiesRisk FactorsSeverity of Illness Index

Stichwörter der Autor:innen

MASHhepatomaliver cancersurveillance

Autor:innen und Institutionen

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.
  • AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.

ORCID-Profile: Nobuharu Tamaki, Beom Kyung Kim, Karn Wijarnpreecha, Pojsakorn Danpanichkul, Cheng Han Ng, Anand V Kulkarni, Ken Liu, Daniel Q Huang

Förderung

  • NCATS NIH HHS
  • NUHS Clinician Scientist Programme
  • NIDDK NIH HHS
  • John C Martin Foundation
  • NHLBI NIH HHS
  • Singapore Ministry of Health's National Medical Research Council
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Tan, D. J. H., Tamaki, N., Kim, B. K., Wijarnpreecha, K., Aboona, M. B., Faulkner, C., Kench, C., Salimi, S., Sabih, A. H., Lim, W. H., Danpanichkul, P., Tay, B., Teh, Y., Mok, J., Nah, B., Ng, C. H., Muthiah, M., Kulkarni, A. V., Lee, S. W., …, & Global Liver Cancer Consortium (2025). Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18346

Vancouver

Tan DJH, Tamaki N, Kim BK, Wijarnpreecha K, Aboona MB, Faulkner C, et al. Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18346

BibTeX
@article{Tan2025,
  author = {Tan, Darren Jun Hao and Tamaki, Nobuharu and Kim, Beom Kyung and Wijarnpreecha, Karn and Aboona, Majd Bassam and Faulkner, Claire and Kench, Charlotte and Salimi, Shirin and Sabih, Abdul-Hamid and Lim, Wen Hui and Danpanichkul, Pojsakorn and Tay, Benjamin and Teh, Yiqing and Mok, John and Nah, Benjamin and Ng, Cheng Han and Muthiah, Mark and Kulkarni, Anand V and Lee, Sung Won and Liu, Ken and Loomba, Rohit and Huang, Daniel Q and Global Liver Cancer Consortium, Global Liver Cancer Consortium},
  title = {Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18346}
}
Kostenlos starten →